Program Interventions to Address Substance Use Disorder and Save Public Healthcare Funds by Massachusetts. Office of the Inspector General.
  
 
Office of the Inspector General 
Commonwealth of Massachusetts  
 
 
Glenn A. Cunha 
Inspector General 
 
  
 
 
 
 
 
 
 
Program Interventions  
to Address Substance Use Disorder 
and Save Public Healthcare Funds 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
March 1, 2017 
One Ashburton Place, Room 1311 | Boston, MA 02108 | (617) 727-9140 | www.mass.gov/ig
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This page is intentionally left blank. 
 
 i 
Table of Contents 
Executive Summary .......................................................................................................................1 
Background ....................................................................................................................................3 
I. The Office of the Inspector General. .......................................................................3 
II. The Medicaid program. ............................................................................................4 
III. The Health Safety Net program. ..............................................................................4 
IV. Opioid use and misuse in the United States. ............................................................5 
Interventions to Address Substance Use Disorders ....................................................................7 
I. Alternative pain treatment......................................................................................10 
II. Revising prescribing policies. ................................................................................11 
III. Increased use of data analytics. ..............................................................................12 
IV. Engaging in outreach and education. .....................................................................14 
V. Removing barriers to treatment. ............................................................................16 
VI. Integration of physical and behavioral healthcare. ................................................17 
VII. Creating interventions for special populations. .....................................................18 
The Cost of Interventions ............................................................................................................21 
Challenges to Measuring the Healthcare and Fiscal Impact of Interventions .......................23 
I. Outcome data is not yet available for newer interventions. ...................................23 
II. Calculating outcome data is challenging when there are simultaneous 
interventions. ..........................................................................................................23 
III. Attributing outcomes based on claims data is difficult. .........................................23 
Impacts of Interventions..............................................................................................................25 
I. Reduced opioid prescribing. ..................................................................................25 
II. Reduced pharmacy spending. ................................................................................25 
III. Reduced healthcare utilization. ..............................................................................26 
IV. Increased screenings. .............................................................................................27 
V. Improved outcomes for pregnant women and their newborns...............................27 
Recommendations and Conclusions ...........................................................................................29 
 
 
 
ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This page is intentionally left blank. 
 1 
 
Executive Summary 
In an earlier report, the Office of the Inspector General (“Office”) examined how the 
Massachusetts Medicaid (“Medicaid”) and the Health Safety Net (“HSN”) programs managed 
over 800,000 fee-for-service claims for certain prescription drugs, with a focus on drugs that 
have a high potential for abuse.
1
  The Office used data analytics to evaluate utilization patterns; 
identify ways for the Medicaid and HSN programs to detect fraud, waste, and abuse; and observe 
what policies and practices the two programs had in place relating to the prescribing and 
dispensing of these drugs.  The report was fueled, in part, by the growing problem of opioid use 
and abuse.  Massachusetts in particular has one of the highest rates of drug overdose deaths in 
the United States; since 2000, opioid-related deaths have increased in Massachusetts by 350%.
2
   
The Office’s earlier report found that the Office of Medicaid (“MassHealth”), the state 
entity that runs both the Medicaid and HSN programs, could better use claims data to target 
fraud, waste, and abuse relating to prescription drugs in both programs.  The report noted that 
using data analytics is an effective way to focus on subsets of MassHealth members or HSN 
users who may be at risk of addiction.  MassHealth could, for example, use data analytics to 
identify MassHealth members or HSN users who are using a particular drug or drug 
combination, and then determine whether the treatment is clinically appropriate.  The report also 
noted that data analytics can identify patterns of prescribing and dispensing controlled substances 
that may indicate fraud or abuse.  The Office further found that MassHealth could take additional 
steps to more effectively manage claims for prescription drugs that have a high potential for 
abuse.  Specifically, the Office recommended that MassHealth focus on how it reviews claims, 
uses prior authorizations, and monitors and addresses its members’ use of Schedule II drugs. 
To follow up on that report, the Office has now examined 12 programs from across the 
country – public and private health insurers, a worker’s compensation program, a hospital-based 
program, and a health system – to identify interventions to address substance use disorder3 with 
the aim of identifying promising practices that MassHealth might replicate.  To the extent 
possible, this examination includes the health outcomes of these practices in an effort to 
determine what interventions have the potential to prevent substance misuse and abuse in the 
first instance.  Effective prevention would, in turn, reduce the need to treat substance use 
disorder; reduce the overall healthcare costs for people with substance use disorder; and lessen 
fraud, waste, and abuse in healthcare spending. This review also examines the available data 
                                                 
1
 Massachusetts Office of the Inspector General, MassHealth’s Administration of Certain Medicaid and Health 
Safety Net Schedule II Drug Claims (Mar. 2016).  Available at http://www.mass.gov/ig/publications/reports-and-
recommendations/2016/masshealths-administration-of-certain-medicaid-and-health-safety-net-schedule-ii-drug-
claims-march-2016.pdf.  The report examined prescriptions for drug treatment agents such as buprenorphine and 
methadone, painkillers such as morphine and oxycodone, sedatives such as certain benzodiazepines, and stimulants 
such as amphetamines.   
2
 Massachusetts Department of Public Health, An Assessment of Opioid-Related Deaths in Massachusetts (2013 – 
2014) (Sept. 2016). Available at http://www.mass.gov/eohhs/docs/dph/stop-addiction/dph-legislative-report-chapter-
55-opioid-overdose-study-9-15-2016.pdf.  
3
 Substance use disorder is the term that the Diagnostic and Statistical Manual of Mental Disorders 5 has used since 
2013 to describe a range of disorders.  The term includes a broad category of addictions (e.g., alcohol, tobacco, 
cannabis, stimulants, hallucinogens, opioids).  Opioid use disorder describes one type of substance use disorder. 
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regarding the fiscal impacts of these interventions in order to identify effective practices that also 
could save public healthcare dollars. 
The interventions the Office reviewed include alternate treatment for pain, revised 
prescription policies, creative uses of data analytics, outreach and education to providers and 
patients, reduction in barriers to treatment for substance use disorder, integration of physical and 
behavioral health services, and tailoring interventions to specific populations.     
Measuring the impact of these interventions is a challenge for a number of reasons. For 
instance, the majority of the programs the Office examined are implementing more than one 
intervention at a time. Therefore, it is difficult to attribute an outcome to one particular 
intervention.  In addition, data is limited because of the short length of time that many of these 
programs have used these interventions.  In spite of the difficulty in documenting the impact of 
specific interventions, some of these programs are seeing positive healthcare and fiscal results.  
Accordingly, the Office recommends that public and private insurance programs, healthcare 
providers, hospitals, and health systems consider adopting the interventions described in this 
report. 
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Background 
I. The Office of the Inspector General. 
Created in 1981, the Office of the Inspector General (“Office”) was the first state 
inspector general’s office in the country. The Legislature created the Office at the 
recommendation of the Special Commission on State and County Buildings, a legislative 
commission that spent two years probing corruption in the construction of public buildings in 
Massachusetts.  The commission’s findings helped shape the Office’s broad statutory mandate, 
which is the prevention and detection of fraud, waste, and abuse in the expenditure of public 
funds and the use of public property. In keeping with this mandate, the Office investigates 
allegations of fraud, waste, and abuse at all levels of government; reviews programs and 
practices in state and local agencies to identify systemic vulnerabilities and opportunities for 
improvement; and assists the public and private sectors to help prevent fraud, waste, and abuse in 
government spending.  
The Office has considerable experience reviewing and analyzing healthcare programs, 
including issues relating to costs, eligibility, documentation, and verification.  The Office also 
has issued a number of analyses, reports, and recommendations regarding the Massachusetts 
Medicaid (“Medicaid”) program, the Health Safety Net (“HSN”) program, healthcare reform, 
and other healthcare topics.   
In July 2016, the Legislature enacted chapter 133 of the Acts of 2016. Section 152 of that 
law directed the Office to study and review the Medicaid and HSN programs: 
Notwithstanding any general or special law to the contrary, in hospital fiscal year 
2017, the office of inspector general may expend a total of $1,000,000 from the 
Health Safety Net Trust Fund established in section 66 of chapter 118E of the 
General Laws for costs associated with maintaining a health safety net audit unit 
within the office.  The unit shall continue to oversee and examine the practices in 
all hospitals including, but not limited to, the care of the uninsured and the 
resulting free charges.  The unit shall also study and review the Medicaid program 
under said chapter 118E including, but not limited to, reviewing the program’s 
eligibility requirements, utilization, claims administration and compliance with 
federal mandates.  The inspector general shall submit a report to the executive 
office for administration and finance and the house and senate committees on 
ways and means on the results of the audits and any other completed analyses no 
later than March 1, 2017. 
Pursuant to this legislative mandate, the Office examined 12 programs from across the 
country – public and private health insurers, a worker’s compensation program, a hospital-based 
program, and a health system.  The purpose of this examination was to identify interventions to 
address the issues surrounding substance use disorder
4
 that the Medicaid and HSN programs 
                                                 
4
 Substance use disorder is the term that the Diagnostic and Statistical Manual of Mental Disorders 5 has used since 
2013 to describe a range of disorders.  The term includes a broad category of addictions (e.g., alcohol, tobacco, 
cannabis, stimulants, hallucinogens, opioids).  Opioid use disorder describes one type of substance use disorder. 
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might replicate.  This examination includes both the fiscal and healthcare utilization outcomes of 
these practices in an effort to determine which strategies may help to prevent substance misuse 
and abuse in the first instance.  Effective prevention would, in turn, reduce overall healthcare 
costs for people with substance use disorder; reduce the need for healthcare spending to treat 
substance use disorder; and lessen fraud, waste, and abuse in prescription drug programs. 
II. The Medicaid program. 
The federal government created the national Medicaid program in 1965 to provide 
medical assistance to low-income Americans, particularly children, through a shared state-
federal commitment.  Today, the national Medicaid program pays for medical care, as well as 
long-term nursing and other care, for tens of millions of Americans.  At the federal level, the 
Centers for Medicare & Medicaid Services (“CMS”) administers the program.  Each state 
administers its own version of Medicaid in accordance with a CMS-approved state plan.  
Although the states have considerable flexibility in designing and operating their Medicaid 
programs, they must comply with applicable federal and state laws and regulations. In 
Massachusetts, the Executive Office of Health and Human Services includes the Office of 
Medicaid (“MassHealth”), which oversees the Medicaid program.  
III. The Health Safety Net program. 
In 1985, the Legislature created the uncompensated care pool (“UCP”) with the goal of 
“more equitably distributing the burden of financing uncompensated acute hospital services 
across all acute hospitals ….”5  The purpose of the UCP was to pay for medically necessary 
services that acute care hospitals and community health centers provided to eligible low-income 
uninsured and underinsured patients.  In addition, the UCP reimbursed hospitals for bad debt for 
patients from whom the hospitals were unable to collect payment.  
In 2006, the Legislature created the Health Safety Net (“HSN”) program, funded by the 
Health Safety Net Trust Fund, to replace the UCP.  The stated purpose of the HSN program was 
to “maintain a healthcare safety net by reimbursing hospitals and community health centers for a 
portion of the cost of reimbursable health services provided to low-income, uninsured or 
underinsured residents of the commonwealth.”6  Initially, the Division of Healthcare Finance and 
Policy managed the HSN program, but in 2012 the Legislature transferred that responsibility to 
MassHealth. 
For ease of reference, this report will refer to individuals who utilize the Medicaid 
program as “MassHealth members” and those who utilize the HSN program as “HSN users.” 
                                                 
5
 G.L. c. 6A, § 75 (repealed 1988).   
6
 G.L. c. 118E, § 66. 
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IV. Opioid use and misuse in the United States. 
The opioid epidemic has reached unprecedented levels in the United States.  More than 
60% of drug overdose deaths in this country involve an opioid.
7
  In 2014, more people died from 
an overdose than in any other year on record, and in 2015 drug overdose deaths and opioid-
involved deaths continued to increase.
8
  The opioid epidemic is linked in part to a liberalization 
of opioid use in the treatment of pain during the 1990s.  In fact, since 1999, the amount of 
prescription opioids sold in the United States has nearly quadrupled, while the amount of 
reported pain has remained unchanged.
9
  The general increase in the availability of narcotics is 
correlated with increased abuse, diversion, and addiction.
10
 Yet the evidence base for the efficacy 
of opioids to treat chronic pain remains limited, with the majority of randomized clinical trials of 
prescription opioids to treat pain having lasted six weeks or less.
11  
In addition to the societal cost, the opioid epidemic has an economic impact.  Generally 
speaking, people with a substance use disorder incur higher healthcare costs than people without 
such a disorder.
12
  For example, one study estimated that opioid overdoses are responsible for 
$20 billion in emergency room (“ER”) and inpatient care for opioid poisoning.13 In addition, 
overall healthcare costs are higher for people with substance use disorders because of the 
medical consequences of the illness.
14
   
In response to the situation, the Centers for Disease Control and Prevention (“CDC”) 
issued new prescribing guidelines in March 2016 that focus on the use of opioids for chronic 
pain in primary care settings.
15
 These guidelines offer 12 recommendations, including discussing 
                                                 
7
 Center for Disease Control and Prevention, Morbidity and Mortality Weekly Report (Jan. 1, 2016).  Available at 
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6450a3.htm.  
8
 Centers for Disease Control and Prevention, Drug Overdose Deaths in the United States Hit Record Numbers in 
2014; Centers for Disease Control and Prevention, Drug Overdose Deaths in the United States Continue to Increase 
in 2015.  Both available at http://www.cdc.gov/drugoverdose/epidemic/index.html.  
9
 Center for Disease Control, National Center for Health Statistics, Wide-ranging online data for epidemiologic 
research (WONDER) (2016).  Available at http://wonder.cdc.gov.  See also Hsien-Yen Chang et al., Prevalence and 
Treatment of Pain in EDs in the United States, 2000 to 2010, 32 American Journal of Emergency Medicine 421-31 
(May 2014). 
10
 Art Van Zee, The Promotion and Marketing of Oxycontin: Commercial Triumph, Public Health Tragedy, 99 
American Journal of Public Health 221-27 (Feb. 2009). “Diversion” refers either to a person who sells his 
prescription drugs or to a person stealing drugs from the intended recipient and using or selling them. 
11
 Thomas R. Frieden & Debra Houry, Reducing the Risks of Relief – The CDC Opioid-Prescribing Guideline, 374 
New England Journal of Medicine 1501-04 (Apr. 2016).  
12
 Behavioral Health Services: Substance Abuse Disorders (n.d.). Available at 
https://www.medicaid.gov/medicaid/benefits/bhs/index.html.  
13
 U.S. Department of Health and Human Services, The Opioid Epidemic: By the Numbers (June 2016).  Available 
at http://www.hhs.gov/sites/default/files/Factsheet-opioids-061516.pdf. 
14
 Robin E. Clark et al., Substance Abuse and Healthcare Costs Knowledge Asset (Mar. 2010).  Available at 
http://saprp.org/knowledgeassets/knowledge_detail.cfm?KAID=21.  
15
 Deborah Dowell et al., CDC Guideline for Prescribing Opioids for Chronic Pain – United States, 2016, 315 
Journal of the American Medical Association 1624-45 (Apr. 2016).  With primary care specialties prescribing nearly 
half of all opioids, educating physicians about the risks of prescribing opioids for chronic pain is critical.  Benjamin 
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the benefits and risks of opioid use with patients, limiting opioid dosage, using alternative 
therapies for chronic pain, using states’ prescription drug monitoring programs, and offering 
medication-assisted treatment for patients with substance use disorders. 
The opioid epidemic has struck Massachusetts particularly hard, resulting in one of the 
highest rates of drug overdose deaths in the nation.
16
  Since 2000, opioid-related deaths have 
increased in Massachusetts by 350%.
17
  In fact, in 2014, the state had a death rate from 
unintentional opioid overdoses of 18.6 individuals per 100,000 people, compared to a rate of 5.3 
per 100,000 in 2000.
18
  In addition, opioid-related deaths are higher among those who have 
obtained opioid prescriptions from multiple pharmacies and those who have obtained 
prescription opioids in combination with certain other prescription medications.
19
   
MassHealth reports that in 2006 it spent approximately $93 million on substance use 
disorder treatment; in 2016, it spent $193 million, more than doubling its spending over ten 
years. This included spending on inpatient and outpatient treatment, detoxification, and 
emergency services, among other forms of treatment. 
In March 2016, Massachusetts passed a law with a number of provisions to address these 
issues, including placing limits on opioid prescriptions, mandating use of the state’s drug 
monitoring programs, mandating that public schools verbally screen students for substance use, 
and improving training guidelines for medical professionals who can prescribe opioids.
20
    
                                                                                                                                                             
Levy et al., Trends in Opioid Analgesic – Prescribing Rates by Specialty, US, 2007 – 2012, 49 American Journal of 
Preventive Medicine 409-13 (Apr. 2015). 
16
 Massachusetts Department of Public Health, An Assessment of Opioid-Related Deaths in Massachusetts (2013 – 
2014) (Sept. 2016). Available at http://www.mass.gov/eohhs/docs/dph/stop-addiction/dph-legislative-report-chapter-
55-opioid-overdose-study-9-15-2016.pdf. 
17
 Id. 
18
 Massachusetts Department of Public Health, Data Brief: Fatal Opioid-Related Overdoses Among Massachusetts 
Residents (Aug. 2015). Available at http://www.mass.gov/eohhs/docs/dph/quality/drugcontrol/county-level-
pmp/data-brief-aug-2015-overdose-county.pdf.  
19
 Massachusetts Department of Public Health, An Assessment of Opioid-Related Deaths in Massachusetts (2013 – 
2014) (Sept. 2016). Available at http://www.mass.gov/eohhs/docs/dph/stop-addiction/dph-legislative-report-chapter-
55-opioid-overdose-study-9-15-2016.pdf. 
20
 2016 Mass. Acts 52. 
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Interventions to Address Substance Use Disorders 
Across the country, many insurance and healthcare programs are implementing a wide 
range of interventions to address the challenges of opioid use and misuse.  Massachusetts has 
recently taken several steps to start addressing these issues.  For example, Massachusetts has a 
new law that, among other things, limits first-time opioid prescriptions for adults to seven days.  
Moreover, it has launched a campaign to reduce the stigma of addiction and treatment and is 
promoting a good Samaritan law to ensure that people who call for emergency assistance will not 
be charged with possession of a controlled substance.
21
 It also is working to improve prescription 
monitoring and expanded prescription drug training for prescribers.  In the long-term, 
Massachusetts will expand medication-based treatment for opioid use disorder; consider gender 
when developing prevention programs; develop post-incarceration treatment plans; and continue 
to use and share data between agencies to improve analysis, tracking, and planning.
22
 A special 
commission studying whether to establish a pain management access program in Massachusetts 
concluded that there is merit in developing a pilot program to facilitate access to pain 
management specialists.
23
 
For its part, MassHealth has developed a statewide database of available treatment 
services, accessible by telephone and internet.  It has also expanded mobile emergency service 
programs, ensured that naltrexone
24
 is included as a pharmacy benefit within all of its plans, and 
reviewed requiring prior authorization for substance use disorder treatment.
25
  It also created a 
new position, Manager of Substance Use Disorder Treatment, and the person in that role is 
responsible for overseeing the delivery of treatment services to MassHealth members. 
In an earlier report, the Office examined how the Medicaid and HSN programs managed 
over 800,000 fee-for-service claims for certain prescription drugs, with a focus on those drugs 
that have a high potential for abuse.
26
  The Office used data analytics to evaluate utilization 
patterns; to identify ways for MassHealth to detect fraud, waste, and abuse; and to observe what 
policies and practices the Medicaid and HSN programs had in place relating to the prescribing 
and dispensing of these drugs.  That report found that MassHealth could better use claims data to 
identify fraud, waste, and abuse relating to prescription drugs in both the Medicaid and HSN 
                                                 
21
 See G.L. c. 94C, § 34A. 
22
 Governor’s Working Group on Opioids, Update 2016 (Sept. 2016). Available at 
http://www.mass.gov/eohhs/docs/dph/stop-addiction/opioid-working-group-update-september-2016.pdf. 
23
 Special Commission to Examine the Feasibility of Establishing a Pain Management Access Program, Preliminary 
Report (Nov. 2016). 
24
 Naltrexone is used to treat opioid use disorder. 
25
 Special Commission to Examine the Feasibility of Establishing a Pain Management Access Program, Preliminary 
Report (Nov. 2016). 
26
 Massachusetts Office of the Inspector General, MassHealth’s Administration of Certain Medicaid and Health 
Safety Net Schedule II Drug Claims (Mar. 2016).  Available at http://www.mass.gov/ig/publications/reports-and-
recommendations/2016/masshealths-administration-of-certain-medicaid-and-health-safety-net-schedule-ii-drug-
claims-march-2016.pdf. The report examined prescriptions for drug treatment agents such as buprenorphine and 
methadone, painkillers such as morphine and oxycodone, sedatives such as certain benzodiazepines, and stimulants 
such as amphetamines.   
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programs.  In particular, the report found that using data analytics is an effective way to focus on 
subsets of MassHealth members or HSN users who are, for example, at high risk for substance 
use disorder.  Once data analytics have identified those members or users, MassHealth can then 
determine whether the patient’s current treatment is clinically appropriate.  Data analytics can 
also identify patterns of prescribing and dispensing controlled substances that may indicate fraud 
or abuse.  The Office further concluded that MassHealth could take additional steps to more 
effectively manage claims for prescription drugs that have a high potential for abuse and 
recommended that MassHealth focus on how it reviews claims, uses prior authorizations, and 
monitors and addresses its members’ use of certain prescription drugs. 
To follow up on that report, the Office reviewed strategies that 12 programs across the 
country are implementing to address opioid prescription misuse and abuse.  The programs 
included a mix of public and private health insurers, workers’ compensation insurers, and 
hospital- and community-based programs.  The goal of this review was to identify strategies that 
MassHealth could implement to improve MassHealth members’ and HSN users’ health 
outcomes by preventing opioid-prescription misuse and by treating it effectively when it arises.  
In addition to improving health outcomes, more effective prevention and treatment can improve 
how public entities use their limited funding by decreasing inappropriate prescribing, reducing 
fraud resulting from prescription misuse and diversion, and lowering healthcare costs (because, 
for example, healthier individuals need fewer healthcare services). 
Virtually all of the 12 programs the Office reviewed implemented more than one 
intervention to address opioid use and misuse; these interventions fall within seven general 
categories:  
 Alternative treatment for pain; 
 Revised prescription policies; 
 Creative uses of data analytics; 
 Outreach and education to patients and providers; 
 Removal of barriers to treatment;  
 Integration of physical and behavioral health services, including increased substance 
use disorder screening by primary care physicians; and 
 Focused treatment for specific populations. 
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The Office will not refer to these programs by name because the purpose of this review is 
to highlight the interventions themselves rather than any particular program.  As illustrated in the 
chart below, the majority of the programs are using multiple interventions: 
Program Interventions Utilized 
A Alternative treatment for pain 
Revised prescription policies 
Outreach and education to patients and providers 
B Revised prescription policies  
Creative uses of data analytics 
Outreach and education to patients and providers 
Removal of barriers to treatment 
Integration of physical and behavioral health services 
C Alternative treatment for pain 
Creative uses of data analytics 
Outreach and education to patients and providers 
Integration of physical and behavioral health services 
D Creative uses of data analytics 
E Alternative treatment for pain 
Revised prescription policies 
Creative uses of data analytics 
Outreach and education to patients and providers 
F Alternative treatment for pain 
Revised prescription policies 
Outreach and education to patients and providers 
G Alternative treatment for pain 
Revised prescription policies 
Creative uses of data analytics 
Outreach and education to patients and providers  
Integration of physical and behavioral health services 
Focused treatment for specific populations 
H Outreach and education to patients and providers 
Integration of physical and behavioral health services 
I Integration of physical and behavioral health services 
Focused treatment for specific populations 
J Outreach and education to patients and providers 
Integration of physical and behavioral health services 
Focused treatment for specific populations 
K Creative uses of data analytics 
Outreach and education to patients and providers 
L Integration of physical and behavioral health services 
Focused treatment for specific populations 
These approaches are described below. 
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I. Alternative pain treatment.  
One theme across several programs was the importance of providing alternative pain 
therapy.  By managing pain with alternative therapies, patients may never have to use opioids or 
may use them for a shorter period of time, thus reducing the risks of addiction.  Further, more 
states are restricting access to opioid prescriptions.  Without adequate pain therapy, simply 
restricting access to opioids may lead to patients turning to illegal opioids or alcohol to address 
their pain.  Alternate pain treatments include chiropractic services, physical therapy, cognitive 
behavioral therapy (“CBT”),27 acupuncture, osteopathic manipulative treatment,28 injections, 
surgery, and non-opioid pain-modulating drugs (e.g., Lyrica, Cymbalta). 
For example, Program G has developed an extensive alternative pain management 
program and is willing to pay for alternative treatments even if there is not yet strong evidence in 
support of their efficacy.  Program G recognized that it needs to replace opioids with some type 
of alternative and was willing to explore various options to see what best meets patients’ needs.  
This program initially focused on CBT and offers CBT programs at several locations, as well as 
through telehealth where the program does not offer it in person.
29
  Program G also developed a 
chronic-pain clinic for patients, which includes weekly meetings both in person and through 
telehealth.  The chronic-pain clinic provides eight sessions in which patients learn about the 
benefit of physical therapy, acupuncture, yoga, mindfulness, adequate sleep, and nutrition.  This 
program also offers yoga classes both on site and online.  Program G has also trained more than 
two dozen of its physicians in an abbreviated form of acupuncture.
30
  The evidence around this 
intervention is still emerging, but both providers and patients have had positive feedback about 
how the alternate pain treatments have improved patients’ pain levels and decreased opioid 
prescriptions.   
Several of the insurers in this review, including Programs A, C, and F, are now 
reimbursing providers for alternative treatments for chronic pain.  Indeed, Program F requires 
patients with chronic pain to try alternative therapies before opioids.     
Programs C, F, and G reported that they have found that managing patients’ expectations 
regarding their pain levels is also a key issue.  These programs indicated that it is important that 
some patients with chronic pain recognize that although their pain may never disappear 
completely, their insurer, provider, or hospital is committed to help find treatments that will get 
their pain to a manageable level.  In conjunction with managing patients’ expectations, Program 
                                                 
27
 CBT is goal-oriented psychotherapy that approaches problem-solving using a hands-on approach, which has a 
small but statistically significant effect on pain and disability. 
28
 Osteopathic manipulative treatments involve an osteopathic physician diagnosing and treating physical pain by 
manipulating a person’s bones and muscles. 
29
 Telehealth is the use of electronic information and telecommunications technologies to support long-distance 
clinical healthcare. 
30
 A physician places small needles in one or both of the patient’s ears.  It takes the physician approximately five 
minutes to place the needles in specific points on the ear that are believed to relieve pain.  The needles remain in 
place for several days until they fall out.  This intervention takes less time and space than traditional acupuncture 
and physicians can learn how to administer it in a half-day class.   
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C is also explicitly focusing on attaining the highest level of patient functionality rather than 
completely eliminating pain. 
Thus, a number of the programs in this review are creating ways for patients to obtain 
alternate treatments for chronic pain.  This approach acknowledges that patients are seeking 
opioid prescriptions for a specific reason – to alleviate pain – and endeavors to treat that pain 
differently. 
II. Revising prescribing policies. 
A. Changing prescription limits.  
To address opioid prescription misuse and abuse, several programs have changed their 
prescribing policies.  Programs E and F, for example, revised their policies to track the CDC’s 
March 2016 prescribing guidelines, which advise caution when increasing a person’s prescribed 
dose above 50 mg morphine milligram equivalents (“MME”) per day and recommend avoiding 
any doses greater than 90 mg MME per day.
31
 Another change among the programs under 
review was setting prescribing limits with regard to either the number of doses prescribed per 
day (Program E) or of the number of days’ supply that a healthcare provider can prescribe at 
once (Program B).   
Program F also implemented a prior authorization requirement for any opioid dose 
exceeding 30 mg MME per day, up to a maximum allowed dose of 300 mg MME.
32
  Program B 
initially limited prescriptions for opioids to a fifteen-day supply but subsequently reduced it to a 
seven-day supply.  After that, patients are able to obtain one refill for an additional seven days, 
but any refills beyond that require prior authorization.  In addition, when seeking prior 
authorization, Program B’s providers must attest that they have entered into a treatment 
agreement with their patients that explains the risks of opioid treatment.
33
 
Finally, patients in Program F with certain conditions no longer qualify for treatment with 
opioid medications without first obtaining a second opinion supporting the use of opioids.  This 
program has anecdotally heard that some providers are pleased with the variety of options now 
available and appreciate being able to tell patients that they must try alternative therapies before 
they can obtain opioids.  However, not all providers have embraced the new policy because 
working to connect patients to alternative pain therapies takes more time than writing a 
prescription.  
                                                 
31
 The dose of an opioid can be measured in morphine milligram equivalents (“MME”), which is also sometimes 
referred to as the morphine equivalent dose (“MED”). 
32
 The prior authorization requirement does not apply to certain types of patients, including cancer patients; patients 
in end-of-life care, nursing homes, or inpatient care; and patients with HIV/AIDS. 
33
 This requirement does not include oncologists. 
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B. Switching from brand-name to generic prescriptions.  
Although Program E has not banned providers from prescribing brand-name opioids, it is 
using provider engagement and education to encourage providers to prescribe generic-equivalent 
opioids.  Brand-name drugs have a much higher “street” value than generic drugs.  By reducing 
the availability of brand-name opioids, Program E believes that fewer prescription opioids will 
be diverted into the community, causing the price of such drugs to rise, making them less 
accessible, and therefore preventing people from starting down the path to illegal opioid use.  
Ultimately, this program’s goal is to decrease the supply of prescription opioids in the 
community and in schools to prevent teenagers from becoming addicted to prescription opioids 
and then switching to heroin.   Program E reported that it has achieved significant reductions in 
brand name-opioid prescriptions. 
III. Increased use of data analytics. 
Many programs are using data analytics to proactively identify patients at risk of 
developing chronic pain, as well as those who are using high levels of opioids.  Some of these 
programs only use claims data, while others draw on additional data sources to predict patients at 
risk of opioid prescription misuse and abuse.   
A. Identifying patients at risk of developing chronic pain.  
Rather than looking at opioid use directly, Program K has developed a unique way to 
identify patients at risk of developing chronic pain.  The goal of this computer model is to 
proactively reduce the number of patients seeking to initiate opioid use.  Program K has 
determined that people with conditions lasting 30 days or more are most likely to develop 
chronic pain.  As a result, the computer model first identifies people with conditions that have 
lasted for 30 days.  The model then monitors those people every 30 days during which they 
continue to seek treatment for those conditions.  To identify those who are at risk for developing 
chronic pain, the model uses information from various claim fields, including those regarding 
pharmacy utilization, musculoskeletal issues, behavioral and psychosocial issues, and 
comorbidities.
34
   
Once the model has identified a patient who is at risk of developing chronic pain, 
Program K evaluates whether there is a concern regarding either opioids or certain combinations 
of prescriptions.  If there is a concern, the program then reaches out to the patient’s doctor.  The 
program also has nurses and other healthcare professionals who may reach out to the patients 
themselves and perform addiction screening.   
                                                 
34
 Comorbidities refer to the presence of two or more chronic diseases or conditions.  Here it refers to the disease or 
injury that is causing the pain along with other diseases or conditions, such as nutritional deficiencies, obesity, 
diabetes, vascular disease, chronic obstructive pulmonary disease, tobacco use, substance use (including alcohol 
use), and osteoporosis. 
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B. Identifying patients using high levels of opioids.  
Several other programs have developed algorithms to identify patients at highest risk for 
opioid prescription misuse and abuse.  Program E developed an algorithm for all patients who 
are prescribed opioids.
35
 The algorithm determines a risk score for each patient by analyzing 
factors from the patient’s records, such as the number of prescribers, number of care providers, 
and the use of multiple pharmacies.
36
  The data analytics team uses this statistical analysis to 
identify patients who have anomalous activity (such as using several different pharmacies over 
short periods of time).  The data team then communicates this information to the program’s 
physicians and other clinicians to develop action plans for how to treat high-risk patients.  The 
partnership between the data team and the clinical team has been critical to the program’s 
success.  Program E also has opioid committees, which include physicians, pharmacists, drug 
education coordinators, data analysts, nursing administrators, and others.  The data analytics 
team meets with the opioid committees to review data and determine if there is any data in need 
of validation. 
Program F has been using data from its state’s prescription monitoring program to 
identify patients at risk for addiction and prescription drug fraud.  A prescription monitoring 
program (“PMP”) is a website where all pharmacies report patients’ prescriptions.  This allows 
prescribers to have access to a patient’s prescription history regardless of whether the person 
used cash or insurance to pay for the prescription.   
Program F has found PMP data to be more helpful than pharmacy claims data alone 
because people with high levels of opioid utilization often pay cash and the program does not 
know about prescriptions for which it does not pay.  Program F has also worked with a 
consulting company to use demographic and other non-claims data to identify people at higher 
risk of addiction.  From this data, the program identifies the providers with the most at-risk 
members and then conducts outreach to screen the program’s patients for opioid abuse.   
Program C uses data analytics to identify people at high risk for addiction by analyzing 
claims data from the CMS.  This program looks for a variety of factors in the claims data to 
identify people at risk for addiction, including treatment for overdose in an emergency room; 
opioid prescriptions greater than 120 mg MME;
37
 and patients with at least three different 
providers, three different pharmacies, or three different opioid prescriptions.  Once Program C 
has identified people at high risk, the program reviews the information about each person 
individually as some of these factors alone may not be an indicator of opioid misuse.
38
 This 
program also recognizes the inherent weaknesses in using claims data, including the three-month 
lag between when the claims occurred and when it receives the data from CMS.  Therefore, 
                                                 
35
 This program excludes from review those patients with cancer and terminal illnesses. 
36
 These factors tend to indicate that a patient is doctor or pharmacy “shopping” to obtain multiple prescriptions at 
the same time. 
37
 See footnote 31. 
38
 For example, a patient may have seen three providers within the same practice.  This would not ordinarily be a red 
flag for doctor-shopping because the patient could not hide treatment by providers who work together and share 
patient records. 
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Program C also has regular weekly provider meetings to discuss patients who may be at risk for 
opioid addiction.  During these provider meetings, the providers share information about patients 
from non-claims sources – including information gained from home visits – and re-formulate 
care plans as necessary.   
Program G has developed a screen within its electronic medical record system that allows 
providers to quickly identify those patients with high levels of opioid use who may be at risk for 
overdose. The screen shows Program G’s providers all of their patients who have been 
prescribed opioids and identifies the ones with the highest risk levels for pain.  The screen 
displays the patients receiving opioids and their daily dose, history of addiction, whether the 
patient takes any other drugs, the date of the person’s last doctor’s appointment, and whether the 
person has an opioid agreement
39
 in place.  Program G is currently developing a similar tool to 
identify patients most at risk for addiction. 
IV. Engaging in outreach and education. 
Many programs noted that a key component of the success of their interventions has been 
outreach and education to both clinicians and patients.  Several noted that it would have been 
difficult to implement a new policy or program without successful provider engagement.  
A. Provider education.  
Nearly all the programs in this review conducted outreach to physicians and other 
medical professionals, both in person or through webinars.  Programs used outreach activities to: 
(1) educate clinicians about new policies being put in place, as well as the risks and benefits of 
opioid use; (2) get feedback from these professionals on ways to improve the programs, as part 
of ongoing quality improvement; and (3) work with physicians who are prescribing opioids at 
higher rates than their colleagues.  
For instance, Program B held a meeting that focused on pain education for providers, 
including primary care and emergency department physicians.  Specialists presented information 
about various alternative pain management options.  Program E conducted outreach to and 
education for all physicians who were prescribing opioids, including physicians in family 
medicine, pain management, orthopedics, and neurology.  Program J focused on teaching 
primary care physicians (PCP”) to screen adolescents for substance use disorder as adolescents 
are often treated for drug overdoses in the ER without follow-up.  Program H conducted a 
similar program targeting patients of all ages.  Program G has trained providers from a variety of 
specialties – including primary care doctors and those in specialties such as anesthesiology, 
rheumatology, neurology, and neurosurgery – in alternative pain management.  This program 
also discusses pain management techniques at its yearly meetings with over 500 physicians.  
Program J also offers in-person trainings that count toward continuing medical education 
(“CME”) credits, which acts as an additional incentive to providers who need CME credits to 
renew their licenses.   
                                                 
39
 Opioid agreements generally inform patients of the risks of taking opioids and provide instructions on safe 
administration. 
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Although some programs emphasized in-person trainings, other programs recognize that 
such trainings and consultations are not always possible.  As a result, virtual resources can play a 
valuable role.  For example, Program H offers online trainings about a screening tool for 
substance use disorder in primary care settings that is evidence-based and endorsed by the 
Substance Abuse and Mental Health Services Administration. 
With regard to engaging providers in policy formulation, Program F utilized a robust 
process to gather feedback from medical professionals about the best approaches to alternative 
pain management.  Once its policies were in place, it again engaged providers to inform them 
about its new pain management policies.  All of these conversations included doctors from 
various hospitals, addiction specialists, pain specialists, and representatives from the state’s 
medical association.   
Two of the programs, Programs A and K, conduct peer-to-peer education for clinicians 
who are prescribing high levels of opioids.  After a patient’s second opioid prescription fill, 
Program A sends the patient and the prescriber an information packet about the risks and benefits 
of opioids.  At this point, the program’s goal is to make sure that opioids are used safely, rather 
than explicitly instructing physicians to lower the dose or duration of the prescription.  However, 
if a patient continues on opioids for more than six weeks, the program sends a nurse case 
manager in person to the physician’s office to discuss prescribing.  If this is not effective in 
reducing opioid prescribing, Program A then has a physician in the same specialty as the 
prescribing physician call that physician to discuss alternative pain management options.
40
   
Program K also reaches out to providers when a computer model identifies a concern for 
the provider’s patients based on either the amount of opioids being prescribed or the combination 
of different prescriptions that the patient is receiving.  The program may decide to call the 
provider, send a letter to the provider with information about the patient’s prescriptions, or have 
a pharmacist or a physician contact the prescriber. 
B. Patient outreach.  
Many programs are also conducting outreach directly to patients who they identify as 
having a high risk of addiction. To conduct this type of outreach, programs stressed the 
importance of having staff who are medical professionals or case managers, rather than claims 
professionals who may not be comfortable or qualified to discuss opioid use and addiction issues 
with patients.   
Program K, which uses a predictive model to identify patients at high risk for chronic 
pain, has nurses and other professionals conduct outreach to those patients.  These healthcare 
professionals call the patients to screen them for potential addiction and then follow up with the 
patient’s provider.   
Program A is implementing an initiative in which it identifies when a person fills a first 
opioid prescription so that the program can start monitoring the patient.  After the second 
                                                 
40
 Program A specifically trains the physicians who conduct the peer-to-peer outreach before they begin making 
these calls. 
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prescription fill, the program provides the patient with a packet of information about the risks 
and benefits of opioids, pain tools, a sample patient “opioid contract,” and other resources.   
Program B, which serves a large homeless population, contracts with a behavioral health 
provider to identify people with addictions and to engage this traditionally difficult-to-engage 
population in treatment.  This program also reaches out to patients who have overdosed in the 
past to see if they want to enroll in a care management program.   
Program I has community health workers reach out to patients who are receiving 
treatment in outpatient substance use disorder clinics to conduct health assessments and connect 
them to PCPs and other health services they may need.  The goal of this program is to connect 
patients to sources of healthcare other than the emergency room to reduce emergency visits and 
save costs. 
Yet another program is conducting outreach to people that it identifies to be at high risk 
of overdose: Program C conducts home visits for its participants, many of whom have chronic 
disabilities.  Health outreach workers screen patients for opioid misuse or abuse during the home 
visit; patients that the health workers identify as at high risk of overdose may receive certain 
tools, such as a locked pill dispenser, which the outreach worker fills once a week. The patient 
can only open the pillbox at predetermined times to take a specific dose of medication.  This tool 
is particularly useful when prescribers are concerned about pill diversion to other family 
members.   
For every person taking opioids for more than 90 days, Program G sends a cover letter 
and pamphlet describing how to take opioids responsibly, along with an educational DVD that 
reviews the components of the program’s opioid agreement.  This opioid agreement outlines the 
risks and benefits of opioid use, the patient’s goals for long-term opioid therapy, and the 
alternative treatment options available.  All patients must sign the opioid agreement, which the 
program considers to be an informed consent document.  Moreover, Program G offers patients 
the option to attend a group class to review the forms and ask questions before signing the opioid 
agreement.  Program G has encountered some resistance from patients who are concerned that 
their pain cannot be managed adequately without opiates, which highlights the importance of 
patient education. 
V. Removing barriers to treatment.  
In addition to encouraging the use of alternative pain management, programs are also 
working to ensure that their policies do not present barriers to seeking treatment for substance 
use disorders.  For example, Program B no longer requires prior authorization for two 
medications – Suboxone and Vivitrol – used to treat opioid dependence.  By doing so, Program 
B hopes to facilitate access to these medications for patients who need them and has seen an 
increase in prescriptions for these drugs since removing the prior authorization requirement.  
Even though these drugs are expensive, the program expects to see a return on its investment 
over the long-term because the cost of the drugs is modest compared to the total medical costs 
for patients with addiction.   
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Also, Program G is expanding access to treatment by increasing the number of providers 
in its system with Suboxone licenses as federal law limits the number of patients one provider 
can treat with Suboxone at a time.
41
  Programs that have removed barriers to accessing drugs to 
treat opioid addiction report increases in pharmacy costs over the short term, though they expect 
this investment to lead to long-term cost savings.   
VI. Integration of physical and behavioral healthcare. 
A number of programs identified the integration of physical and behavioral healthcare as 
another key component to addressing substance use disorder.  Recognizing that primary care 
visits are often the only time that a patient interacts with the healthcare system, several programs 
require PCPs to screen for addiction and substance use disorder.  After PCPs screen patients, 
they can refer those with positive screenings to behavioral health service providers.  Programs 
believe that training PCPs to detect potential addiction early may help prevent future ER visits 
and negative health outcomes for patients.     
Program H, which has PCPs screen for addiction and substance use disorder, has 
developed a behavioral health hotline that PCPs can call for guidance on referring patients to 
appropriate behavioral health providers.  The program worked with the state’s Medicaid program 
to develop a new code to allow providers to bill for the screening.  Program H is also planning to 
expand its physician-training program beyond PCPs to include OB-GYNs, who act as PCPs for 
many women.   
In another example of behavioral health integration, Program B has created integrated 
care management teams in which physicians and social workers work together.  This allows a 
patient to have one point of contact regardless of whether his issue is physical or behavioral.  
Program C has patient care teams that include a licensed mental health clinician, which helps to 
keep the program’s focus on providing physical and behavioral health services in a streamlined 
manner.  It also helps the providers to recognize when a particular patient has both physical and 
behavioral health issues.   
The lack of integration of physical and behavioral health can present a major challenge to 
programs.  For example, Program I’s state recently removed substance use disorder treatment 
services from the Medicaid managed care program.  This means that managed care providers can 
no longer provide treatment for substance use disorder.  As a result, it is difficult for this 
managed care program to know which patients are receiving substance use disorder treatment 
and therefore may not be providing the necessary care to those patients.  Although Program I 
aims to link its patients with substance use disorder to PCPs and other treatment for physical 
health conditions, the lack of integration between behavioral health services and other healthcare 
has presented a challenge. 
                                                 
41
 21 U.S.C. § 823(g)(2)(B). 
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VII. Creating interventions for special populations. 
Some programs are implementing interventions focused specifically on unique 
populations.  In addition to the program providing services to a large number of homeless 
patients,
42
 two other programs in this review are tailoring interventions to best address addiction 
in populations with specific characteristics and needs. 
A. Adolescents. 
After looking at its data, Program J recognized that a large number of adolescents were 
being treated in the ER for drug poisoning, but that only a few received follow-up care after the 
ER visit or had had any previous office visits during which their physician identified a substance 
use disorder.  Program J recognized that PCPs may not believe that substance use is an issue 
among their adolescent patient population.  
To combat this misperception, Program J’s staff conducts outreach to physicians’ offices 
with data to demonstrate that substance use is a local problem among their patients.  The 
program also trains physicians to use a screening tool specific to adolescents, known as the 
CRAFFT screening tool, which the American Academy of Pediatrics’ Committee on Substance 
Abuse recommends.
43
  Program J has trained physicians on the use of the CRAFFT tool and 
providers may receive reimbursement for conducting screenings.  
The programs that have trained PCPs to screen for substance use disorder have 
documented increased substance use disorder screenings.  Program J, which is working with 
adolescents, noted that before it began educating PCPs to screen their adolescent patients for 
substance use disorder, none of the PCPs had screened their patients.  However, at six-month 
follow-up, 50% of the patient records in the intervention group documented some screening for 
substance use disorder.
44
  Finally, Program H reports that it has had approximately 5% of its 
members screened by PCPs during the first year of its interventions. 
B. Pregnant women and their newborns. 
Program L is focusing on treating pregnant women with opioid addiction.  A patient care 
manager coordinates the care for these women and provides Suboxone treatment in conjunction 
with obstetric services, behavioral health treatment, and social services.  Some of the social 
services to which Program L links women include a transportation liaison who helps them get 
bus tickets to and from the clinic, daycare in the clinic, an on-site nutritionist who helps them 
apply for WIC and other services, and a program to address domestic violence.  Other services 
include employment placement assistance, especially for those with prior felonies, and housing 
                                                 
42
 See page 16. 
43
 The name of this tool is a mnemonic acronym of the first letters of key words in its six screening questions (car, 
relax, alone, forget, friends, trouble).  For more information, see http://www.ceasar-boston.org/CRAFFT/. 
44
 None of the providers in the intervention group had billed for this service, however, and the program plans to 
continue to encourage providers to bill for it.   
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assistance.  Program L treats women for up to six weeks postpartum, after which they are 
transferred to a community Suboxone provider.  
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The Cost of Interventions 
Few of these programs have calculated the costs of implementation.  As a result, it is 
difficult to determine whether their interventions generated cost savings.  However, a few 
programs were able to give rough estimates of the cost of program implementation.  For 
example, Program H stated that it has spent about $50,000 to reimburse providers who trained 
other providers how to screen for substance use disorder in a primary care setting.   
Other programs said that their interventions did not necessarily cost anything to 
implement or that they simply redirected existing staff and resources to fund them.  For example, 
Program F explained that it did not need any funding to implement its new prior authorization 
policy, since the pharmacy benefit manager was already in place and only needed to follow the 
new guidance concerning the prior authorization.   
Some programs, such as Program B, stated that the cost of implementing their 
interventions was modest but that they fully expect to get a return on their investments based on 
improved health outcomes for their patients.  Yet other programs do not plan to calculate the cost 
of their interventions, especially if the program did not design the intervention to reduce costs 
but rather to improve patient safety, or if the program has so few enrollees that it does not 
believe the data will be meaningful on a larger scale.   
The interventions that Program A has implemented, such as sending a case manager to 
talk to the patient’s doctor and peer-to-peer reviews, are actually revenue generating because this 
program does not pay for them itself.  Conversely, Program J, which focuses on treating pregnant 
women and their newborns, reduced inpatient admissions for both the mothers and their 
newborns, which in turn reduces revenue for the hospital(s) that treat the mother and baby.  This 
is an example of a positive healthcare outcome for the patients that creates a financial loss for the 
hospital.  Finally, Program G has hired new staff and shifted many full-time positions to 
implement its alternative treatment programs for pain management but has not calculated the 
cost. 
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Challenges to Measuring the Healthcare and Fiscal Impact of 
Interventions 
Some of the programs in this review have measured the impact of their interventions in a 
variety of ways, in terms of both healthcare utilization and fiscal outcomes.  At the same time, 
several programs have experienced challenges in evaluating outcomes and therefore information 
on fiscal and health outcomes for these 12 programs is generally limited. There are a number of 
reasons for these information gaps, including lack of data, outcome data that is not yet available, 
and the difficulty attributing specific health outcomes to a particular intervention. 
I. Outcome data is not yet available for newer interventions.  
Although many of the programs plan to assess health and fiscal outcomes in the future, 
they have not yet done so.  Many of the programs started working on their interventions within 
the past two years, and want at least three years of data to draw conclusions about the fiscal 
impact of the interventions.   
Programs also noted the need to calculate both short-term expenditures and long-term 
cost savings.  In the short term, for example, alternative pain management such as acupuncture 
and yoga can cost more than opioids.  In the long-term, however, reducing the number of 
patients on opioids will likely both reduce the number of overdoses and the overall use of the 
healthcare system, both of which would save money.   
II. Calculating outcome data is challenging when there are simultaneous interventions. 
Another challenge in tracking health and fiscal outcomes is that many programs are 
implementing numerous interventions simultaneously, some for substance use disorders and 
some for other conditions.  For example, a program may have multiple initiatives to reduce all 
emergency room visits and inpatient admissions, including one for patients with substance use 
disorder.  These overlapping interventions make it difficult to assess the impact of the 
intervention (or interventions) related to the substance use disorder.   
III. Attributing outcomes based on claims data is difficult.  
One way of measuring positive outcomes from substance use disorder interventions 
would be to focus on changes in specific types of health service utilization.  However, programs 
noted that calculating such outcomes presents its own set of challenges.  For example, using 
emergency room claims data to identify overdoses is difficult because the claims may contain 
many different designations. Thus, if an overdose resulted in cardiac arrest, the primary 
diagnosis would likely be cardiac arrest rather than the overdose.  As a result, overdose may be 
far down the list of diagnoses or not even included on the claims form.  Further, emergency room 
claims involving opioids may be coded as poisonings or suicide attempts rather than overdoses, 
which compounds the difficulty of using claims data to evaluate outcomes.  Moreover, diagnoses 
on claims represent an interpretation from a healthcare coder.  With the significant number of 
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possible codes, there is tremendous variation in how substance use disorder treatments are listed 
on claims.   
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Impacts of Interventions 
I. Reduced opioid prescribing. 
Although the number of programs in this review that have been able to assess changes in 
fiscal outcomes and health service utilization is limited, some programs have documented 
changes in opioid prescribing after implementing their interventions.  For example, Program A 
conducted a controlled trial to compare pharmacy costs and other outcomes between an 
intervention group and a control group. The patients in the intervention group had case managers 
and their physicians received prescriber education.  Program A found:  
 There was a 14% reduction in opioid prescriptions and a 22% reduction in 
pharmacy spending for the intervention group. 
 The average pharmacy cost per patient per month for the intervention group 
was less than half the cost for the control group.   
 The average opioid cost per patient per month for the intervention group was 
less than half the cost for the control group. 
 The average daily MME45 was 39 mg in the intervention group compared to 
46 mg in the control group. 
 The intervention group received opioids for 13% fewer days than the control 
group.  
Another program, Program F, has seen a 36% decrease in opioid prescriptions.  Yet 
another, Program G, has seen a nearly 75% reduction in patients on high doses of opioids (over 
100 mg MME per day).  One program, Program E, has reduced prescribing of OxyContin by 
almost 80% (measured by milligrams prescribed).  After implementing its model to prevent 
chronic pain, Program K saw a 50% reduction in the number of claims for opioids, as well as a 
roughly 25% reduction in the average daily MME. 
II. Reduced pharmacy spending.  
Some of the programs have documented reduced pharmacy spending after implementing 
their interventions.  For example, Program K, which implemented a predictive model to identify 
patients at risk of developing chronic pain, has seen a nearly 50% reduction in the cost of 
pharmacy claims for patients that the model identified.  The reduction in cost occurs when, once 
the model identifies the patients at risk, the program reaches out to the patient and the patient’s 
healthcare provider about appropriate opioid use and the dangers associated with improper use.  
Thus, this appears to be a promising approach. 
As described in the previous section, Program A conducted a controlled trial to compare 
pharmacy costs and other outcomes.  Program A found a 22% reduction in overall pharmacy 
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 See footnote 31. 
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spending for the intervention group.  The program also found a significant reduction in total 
opioid costs and average prescription costs between the intervention and the control group.  
A third program – Program G – tracked spending on opioids before and after its 
interventions, which include a number of initiatives to promote alternative treatments for pain.  
Program G found that pharmacy spending on opioids has fallen by about 30% since the 
beginning of its program approximately seven years ago.   
Conversely, programs that have removed barriers to accessing drugs to treat opioid 
addiction report increases in pharmacy costs over the short term, though they expect this 
investment to lead to long-term cost savings.  For example, after removing prior authorization 
requirements for prescription drugs to treat substance use disorder, Program B has seen an 
increase in the prescribing of Suboxone and Vivitrol, both of which are expensive.  However, 
this program indicates that these drug costs are modest compared to the total medical costs for 
patients with substance use disorder.  
Similarly, although the costs of alternative pain management therapies may exceed the 
pharmacy costs of prescribing opioids, several programs indicated that they expect cost savings 
in the long run through the reduction in healthcare costs related to treating people with opioid 
addiction.  
III. Reduced healthcare utilization.  
Because the programs in this review utilize a number of initiatives targeting opioid abuse, 
it can be difficult to disentangle the relative impact of each intervention on the cost of healthcare 
utilization.  In spite of this difficulty, some programs have measured reductions in healthcare 
utilization, including the reduction in inpatient admissions, ER visits, and the length of hospital 
stays.  For example, Program B found after one year that: 
 Emergency room visits decreased by 14%. 
 Emergency room visits related to substance use disorder (excluding alcohol) 
dropped 16%. 
 Inpatient admissions decreased by 5%. 
 Inpatient admissions related to substance use disorder (excluding alcohol) fell 
by 31%. 
Furthermore, Program K noted reductions in pharmacy-related adverse events and in 
surgical rates to address pain-related conditions.  Pharmacy-related adverse events include both 
negative reactions to over-the-counter drugs, such as Tylenol and Benadryl, as well as overdoses 
on opioids and other prescription drugs.  With regard to a reduction in surgical rates, Program K 
reported a lower number of lumbar and shoulder surgeries to treat pain-related conditions.  
Finally, Program E reported a 21% reduction in opioid-related adverse events.   
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IV. Increased screenings.  
The programs that have trained PCPs to screen for substance use disorder have 
documented increased screenings.  Program J, which is working with adolescents, noted that 
before it began educating PCPs to screen their adolescent patients for substance use disorder, 
none of the PCPs had screened their patients.  However, at the six-month follow-up, 50% of the 
intervention group had received some screening for substance use disorder.  Program H reports 
that it has had approximately 5% of its members screened by PCPs during the first year of its 
interventions. 
V. Improved outcomes for pregnant women and their newborns.   
Program L, which works with pregnant women and their newborns, has had measurable 
successes.  Specifically, 48% of the women in the program graduated, which means that the 
women were treated throughout their pregnancy, through six weeks postpartum, and then 
transferred to a community Suboxone provider.  The typical completion rate for Suboxone 
treatment is 35%. 
Program L has also been able to track data on healthcare utilization, both for the women 
who are enrolled in their program and for their newborn infants. The program reports a reduction 
in the length of inpatient stays for babies born to mothers who are part of the program and who 
are receiving Suboxone treatment.  This results in significant cost savings as these babies 
typically require a stay in the neonatal intensive care unit (“NICU”) if they are being treated for 
addiction.  The program reports the following results: 
 The average length of stay in a NICU for babies with mothers in the program 
is half the length of time for babies whose mothers are receiving methadone 
treatment.   
 35% of babies in this program require medication to treat neonatal abstinence 
syndrome, compared to 45% of babies of mothers treated by community 
buprenorphine providers and 60% of babies of mothers treated with 
methadone. 
There is an opportunity in Massachusetts to learn more about how to care for pregnant 
women and their newborns.  The Massachusetts Health Policy Commission recently provided 
almost $3 million in grants to six hospitals to develop or improve interventions relating to 
neonatal abstinence syndrome, which will improve care for infants with neonatal abstinence 
syndrome, as well as for women in treatment for opioid use disorder during and after pregnancy.  
One goal of these grants is to demonstrate that an integrated delivery model for these infants and 
families will result in cost savings and quality improvements.  Three hospitals will work with 
infants who show symptoms of neonatal abstinence syndrome and three hospitals will work with 
pregnant women with opioid use disorder.  The three hospitals working with infants will, among 
other interventions, increase their focus on non-pharmacologic care, improve pharmacologic 
care, initiate new hospital care models, and implement a multidisciplinary approach to integrate 
pre- and post-natal management of the mother and baby.  The three hospitals working with 
pregnant women will, among other interventions, treat the women and babies from pre-natal 
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screenings through six or twelve months postpartum with pharmacotherapy, behavioral 
healthcare, prenatal care, life skills education, breastfeeding, newborn care, lifestyle coaching, or 
alternative treatment for addiction.  One of these hospitals will also provide enhanced training 
for clinicians regarding neonatal abstinence syndrome.   
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Recommendations and Conclusions 
This review has discussed the interventions that different healthcare and insurance 
programs are implementing to address opioid prescription misuse and abuse, including both the 
fiscal and healthcare utilization outcomes of these practices, in an effort to determine which 
strategies may help to prevent substance misuse and abuse in the first instance.  Effective 
prevention would, in turn, reduce the need for healthcare spending to treat substance use 
disorder; reduce the overall healthcare costs for people with substance use disorder; and lessen 
fraud, waste, and abuse in prescription drug programs.  To the extent that MassHealth does not 
provide coverage for these interventions, it should consider doing so to provide additional 
options to MassHealth members and HSN users with substance use disorders. 
Many of these interventions have the potential to be replicated or adapted by other 
insurers or programs.  Some of these interventions have demonstrated positive fiscal or health 
outcomes; other interventions either do not have documented outcomes or are too new to show 
what fiscal or health impact they might have.  These interventions occur at the patient, provider, 
insurer, and health system level, and include: 
 Alternative treatment for pain.  Managing pain better with alternative therapies – 
such as physical therapy, chiropractic services, cognitive behavioral therapy, 
acupuncture, osteopathic manipulative treatment, injections, and non-opioid pain-
modulating drugs – means that patients may never have to use opioids or may use 
them for a shorter time, thereby reducing the risks of addiction. 
 Revised prescription policies.  Changing prescription limits, strengthening prior 
authorization requirements, and requiring second opinions for opioid prescriptions are 
all methods of reducing the use of prescription opioids.  Switching from brand-name 
to generic opioid prescriptions may reduce the number of prescription opioids that are 
diverted into the community. 
 Creative uses of data analytics.  Data analytics can identify patients at risk of 
developing chronic pain, as well as those who are currently using high levels of 
opioids.  By identifying these patients, providers have an opportunity to intervene to 
prevent opioid use, or to offer alternatives or treatment.  A strong partnership between 
the data team and the clinical team appears to be critical to successfully using data 
analytics in this regard. 
 Outreach to and education of patients and providers.  Including providers in 
policy development and education has the potential to increase provider buy-in to 
new opioid management interventions.  Educating providers in appropriate 
prescribing practices and alternate pain management can improve the quality of care 
that they provide.  Reaching out to and educating patients can help to promote 
informed consent regarding opioid use, reduce opioid use, reassure patients that there 
are multiple ways to treat their pain, and manage expectations around the reduction – 
not elimination – of pain. 
 Removal of barriers to treatment.  Removing barriers to treatment by eliminating 
prior authorization for medication-assisted treatment for substance use disorder and 
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expanding the number of providers available to treat this disorder can increase 
treatment. 
 Integration of physical and behavioral healthcare.  Training PCPs to identify 
substance use disorder in both adult and teenage patients, as well as integrating 
physical and behavioral healthcare, provide opportunities to increase the 
identification of patients in need of treatment. 
 Focused treatment for specific populations.  Creating treatment programs for 
specific populations, such as pregnant women and their newborns, adolescents, and 
the homeless, can target unique needs that might otherwise go unaddressed. 
There are significant challenges to documenting outcomes resulting from these 
interventions, both in terms of health service utilization and cost savings.  However, the 
outcomes that programs have measured, both in terms of cost savings and improved health 
outcomes, are encouraging.  Several programs have documented significant reductions in opioid 
prescribing, pharmacy spending, ER visits, or hospital length of stay, all of which have the 
potential to lead to reduced healthcare spending.  The availability of outcome data will increase 
as programs obtain several years’ worth of data to document the effects of their interventions.  At 
the same time, preliminary fiscal outcome data should be interpreted with caution, as spending 
may increase on other treatments, such as Suboxone and alternative pain management 
techniques.  However, even these more costly interventions may ultimately lead to cost savings 
in the long-term by decreasing overdoses and the related healthcare expenses, as well as 
decreasing overall healthcare costs by improving health outcomes for people with substance use 
disorders.  
Further, the challenges of measuring the results of these interventions should not deter 
programs from tracking fiscal and health outcomes.  In fact, programs that implement these or 
other interventions must track both fiscal and health outcomes for two reasons.  First, they will 
be able to evaluate the cost and suitability of a particular intervention for their patients.  Second, 
as more documentation becomes available, other insurers, hospitals, and health systems will be 
better able to evaluate which types of interventions are fiscally and clinically appropriate for 
their particular populations. 
The new Massachusetts opioid law provides a foundation for addressing prescription 
opioid misuse and abuse by mandating opioid prescribing limits, provider education and training, 
and screening for substance use disorder in certain settings, among other interventions.  The 
work to address opioid addiction must continue to evolve, however, since 2016 marked another 
increase in the number of opioid-related deaths, with 1,465 confirmed and more than 500 others 
suspected.
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  This review suggests other promising interventions that may help Massachusetts’ 
public and private insurers and healthcare systems to reduce opioid prescription misuse and 
abuse among their patient population and contribute to addressing the opioid epidemic.  
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